Drug Profile
Research programme: aurora kinase inhibitors - GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Pyrazoles; Pyridines; Pyrroles; Urea compounds
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 28 Aug 2011 Early research in cancer in USA (unspecified route)
- 31 Dec 2010 No development reported - Preclinical for Cancer in USA (unspecified route)